Premium
δ‐Tocotrienol tend to attenuate plasma triglyceride levels (829.12)
Author(s) -
Gu Xuan,
Min Byungjick,
Lee Sunok
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.829.12
Subject(s) - tocotrienol , triglyceride , tocopherol , cholesterol , hyperlipidemia , blood lipids , lipid profile , medicine , chemistry , vitamin e , endocrinology , zoology , antioxidant , biology , biochemistry , diabetes mellitus
Tocotrienols have been shown to reduce the risk factors of cardiovascular disease. α‐ and γ‐tocotrienols are predominant forms of tocotrienols on the market. An animal study was conducted to examine the hypocholesterolemic effects of δ‐tocotrienol. 45 male Sprague Dawley rats (6 week old) were randomly assigned into four groups: normal fat control group (NFC) (n=9), high fat control group (HFC) (n=12), pure δ‐ tocotrienol group (dT3) (n=12), and δ‐tocotrienol rich oil group (DGT) (n=12). The NFC received AIN 93 diet (10% of energy from fat) and the other groups received high fat diet (38% of energy from fat) for 3 weeks. The treatment groups were gavaged with 20 mg dT3 and 25.25 mg DGT dispensed in 0.5ml of 5% tween‐eighty. The control groups were treated with the same vehicle alone in the same manner. Blood samples were collected by cardiac puncture for cholesterol profile. Plasma triglyceride was 7% and 12% lower in dT3 and DGT groups than HFC group. No significant differences were found in plasma total and HDL cholesterol levels. The results indicate δ‐ tocotrienol would be assist in lowering plasma triglyceride levels and may reduce the risk of cardiovascular disease. Grant Funding Source : Supported by Arkansas Bioscience Institute (ABI)